Drug Discovery & Development

MAGAZINE
Current Issue
Archives
Upcoming Issues
Advisory Board
Contribute
Meet the Staff

SITE SPONSORS

Advertise with Us

Current Issue:

Structured Drug Design
cos-1

Designing a new drug can be faster and more economical when researchers incorporate computational approaches. Software packages let scientists explore more structural options and even make predictions of the properties of new compounds. continue
Mike May, Contributing Editor

Closer to Human

New knockout rat models can be more effective predictors of pharmacokinetics. continue
Xiaoxia Cui, PhD, R&D Manager; Kristen Bettinger, Product Manager; Phil Simmons, Marketing and Business Development Manager; Edward Weinstein, PhD, Director; Sigma-Aldrich,St. Louis, Mo.

Managing the Research Laboratory for Optimum Decision Making

While there are many challenges to running an efficient research laboratory, data management is one of the most critical issues facing scientists within drug discovery and development. continue
Kim Shah, Vice President, Marketing and Business Development; Thermo Fisher Scientific, Pittsburgh, Pa.

Electronic Trial Master Files
Many organizations operate using an existing “tree” structure, which they’ve employed in previous paper Trial Master File systems. continue
James DeSanti, CEO and Founder; PharmaVigilant, Westborough, Mass.

A Hands-On Approach

To explore the three-dimensional structures of compounds, many researchers use the open-source PyMOL, which is maintained by Schrödinger. continue
Mike May, Contributing Editor

Integrating Informatics
Every drug discovery organization seeks to improve the speed and success of its research efforts. But advances in the field—including high throughput screening, in silico modeling, biotherapeutics, and more—present a double-edged sword. continue
Matt Hahn, PhD, Senior Vice President, Research and Development; Accelrys, San Diego, Calif.

Operationalizing CDISC Data Standards for Efficient Clinical Trial Operations
Data standards are routinely discussed within the life sciences industries today, and many research companies have been piloting the use of CDISC standards within their organization. continue
David Handelsman, Advanced Analytics Strategist, Health and Life Sciences; SAS, Cary, N.C.

Multiple Choices

Pharma companies migrate to high-content screening approaches to screen for kinase inhibitors. continue
James Netterwald, PhD, MT (ASCP), Contributing Editor

Shining a New Light on Proteins

Concentration-gradient dynamic light scattering simplifies protein-protein interaction characterization. continue
Amy D. Hanlon, R&D Engineer; Michael I. Larkin, PhD, Principal Scientist; Ryan M. Reddick, R&D Technician; Department of Research and Development, Wyatt Technology Corporation, Santa Barbara, Calif.

Cannabis in the Mainstream?
pnp

The development of pharmaceuticals derived from cannabis took a major step forward in June when the UK’s Medicines and Healthcare Products Regulatory Agency approved the prescription use of Sativex to treat spasticity due to multiple sclerosis. continue
Ted Agres, Contributing Editor

1 2

Study Demonstrates Benefits of Cannabis for Pain

Botox Case Settled for $600M

Berries Activate Brain's Housekeeping Mechanism

Obama Stem Cell Regulations Temporarily Blocked

More Problems At J&J Subsidiary

Abnormal Weight A Colon Cancer Risk Factor

A Novel Approach to Treating Peripheral Arterial Disease

Japan Confirms Presence of Superbug Gene

NIH Finds Promising Staph Treatment

FDA Approves Tekamlo